Product Description
Allergan was developing agn-201781, an oral drug, for the treatment of postherpetic neuralgia or post-traumatic peripheral neuralgia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00533351)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Neuralgia, Postherpetic|Neuralgia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2007-003787-21 | P2 |
Terminated |
Neuralgia, Postherpetic |
2008-06-20 |
|
NCT00533351 | P2 |
Terminated |
Neuralgia |
2008-06-01 |